End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10.88 CNY | +2.84% | -4.39% | -14.47% |
Dec. 06 | Evotec Says Partner Obtained Regulatory Approval in China for Insomnia Drug | MT |
Dec. 06 | Jingxin Pharmaceutical Gets Nod to Market Didacinil Capsules | MT |
Sales 2023 * | 4.02B 556M | Sales 2024 * | 4.56B 631M | Capitalization | 9.37B 1.3B |
---|---|---|---|---|---|
Net income 2023 * | 676M 93.56M | Net income 2024 * | 756M 105M | EV / Sales 2023 * | 2.33 x |
Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 2.05 x |
P/E ratio 2023 * |
13.9
x | P/E ratio 2024 * |
12.4
x | Employees | 4,101 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 57.17% |
1 day | +2.84% | ||
1 week | -4.39% | ||
Current month | +0.46% | ||
1 month | -0.46% | ||
3 months | -12.47% | ||
6 months | -11.40% | ||
Current year | -14.47% |
Managers | Title | Age | Since |
---|---|---|---|
Tian Qing Hu
CHM | Chairman | 60 | - |
Mei Li Chen
DFI | Director of Finance/CFO | 54 | - |
Gang Lü
CHM | Chairman | 62 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Gang Lü
CHM | Chairman | 62 | - |
Neng Neng Wang
BRD | Director/Board Member | 51 | - |
Zhi Ping Jin
BRD | Director/Board Member | 43 | - |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 115 M€ | +5.14% | - | |
0.00% | 36 M€ | +4.92% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 10.88 | +2.84% | 10,634,250 |
24-03-27 | 10.58 | -2.49% | 8,705,254 |
24-03-26 | 10.85 | +0.93% | 9,756,860 |
24-03-25 | 10.75 | -3.33% | 12,666,010 |
24-03-22 | 11.12 | -1.59% | 12,875,570 |
End-of-day quote Shenzhen S.E., March 27, 2024
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-14.47% | 1.26B | |
+33.46% | 701B | |
+26.24% | 571B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 319B | |
+0.74% | 210B | |
+2.95% | 210B | |
-6.05% | 201B | |
-3.61% | 157B |